Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 21 - Drugs for disorders of the muscular or neuromuscular system
Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
10/2002
10/17/2002WO2002080941A1 Compositions for preparing external carbon dioxide agents
10/17/2002WO2002080927A1 Use of selective cox-2 inhibitors for the treatment of urinary incontinence
10/17/2002WO2002080851A2 Chimeric vaccines
10/17/2002WO2002036605A9 Estrone-derivatives having cytoprotective activity
10/17/2002WO2002029061A3 G-protein coupled receptors
10/17/2002WO2001098323A3 G-protein coupled receptors
10/17/2002WO2001091778A3 Compositions for treating neck and shoulder discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins
10/17/2002WO2001041760A8 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/17/2002US20020152481 Genetic engineering; qualitative analysis
10/17/2002US20020151551 Use of growth hormone secretagogues in conjunction with physical exercise cross reference to related application
10/17/2002US20020151009 Human polynucleotides, polypeptides, and antibodies
10/17/2002US20020150624 Mixture of drug, aminoacrylate polymer and acid
10/17/2002CA2762966A1 Hsa-free formulations of interferon-beta
10/17/2002CA2479780A1 Antisense calpain nucleotides and uses thereof
10/17/2002CA2446462A1 Chimeric vaccines
10/17/2002CA2443031A1 Use of selective cox-2 inhibitors for the treatment of urinary incontinence
10/17/2002CA2442313A1 Methods for treating the inflammatory component of a brain disorder
10/17/2002CA2441499A1 Method for producing a vaccine
10/16/2002WO2001079186A1 2-guanidino-4-arylchinazolines as nhe-3 inhibitors
10/16/2002EP1248849A1 Obg3 globular head and uses thereof for decreasing body mass
10/16/2002EP1248801A1 Human polynucleotides, polypeptides, and antibodies
10/16/2002EP1248612A1 Novel compounds and compositions as protease inhibitors
10/16/2002EP1140065A4 Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
10/16/2002EP0927161B1 Substituted cyclic amine metalloprotease inhibitors
10/16/2002CN1374967A Compounds for the treatment of ischemia
10/16/2002CN1374952A Benzimidazolone derivatives and their use as phosphodiesterase inhibibors
10/16/2002CN1374866A Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
10/16/2002CN1374859A 药物粉剂 Drug powder
10/16/2002CA2406161A1 2-guanidino-4-arylquinazolines as nhe-3 inhibitors
10/15/2002US6465445 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
10/15/2002US6465003 Drug delivery
10/15/2002CA2253795C Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors
10/10/2002WO2002079448A2 G-protein coupled receptors
10/10/2002WO2002079441A2 Secreted proteins
10/10/2002WO2002079404A2 Cytoskeleton-associated proteins
10/10/2002WO2002079236A1 Alpha conotoxin peptides with analgesic properties
10/10/2002WO2002079221A2 Sapogenin derivatives, their synthesis and use
10/10/2002WO2002079197A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/10/2002WO2002079169A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
10/10/2002WO2002079155A1 Pyrrolidine sulfonamides
10/10/2002WO2002079146A2 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
10/10/2002WO2002078682A2 Estrogen replacement therapy
10/10/2002WO2002078643A2 Immunomodulation and effect on cell processes relating to serotonin family receptors
10/10/2002WO2002078641A2 Pyrrolidine sulfonamides
10/10/2002WO2002046373A8 Method of collecting placental stem cells
10/10/2002WO2002046178A3 Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors
10/10/2002WO2002004612A3 Drug metabolizing enzymes
10/10/2002WO2001098353A3 Secreted proteins
10/10/2002WO2001077174A3 Human transporters and ion channels
10/10/2002US20020147198 Substituted arylamine derivatives and methods of use
10/10/2002US20020147192 Viricides; antiinflammatory agents; antiallergens; antiarthritic agents
10/10/2002US20020146759 Stress proteins and peptides and methods of use thereof
10/10/2002US20020146417 Administering function blocking antibody or a fragment antibody, capable of binding an epitope of VLA-1 to provide a decrease in arthritic score of about 65% or greater when compared to control antibody treated subject
10/10/2002DE10116589A1 Use of creatine for reducing oxidative stress e.g. for treating aging, neurodegeneration and cancers
10/10/2002CA2443050A1 Immunomodulation and effect on cell processes relating to serotonin family receptors
10/10/2002CA2442495A1 Alpha conotoxin peptides with analgesic properties
10/10/2002CA2442484A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
10/10/2002CA2442150A1 Sapogenin derivatives, their synthesis and use, and methods based upon their use
10/10/2002CA2442064A1 G-protein coupled receptors
10/10/2002CA2442062A1 Secreted proteins
10/10/2002CA2441654A1 Cytoskeleton-associated proteins
10/10/2002CA2441252A1 Estrogen replacement therapy
10/10/2002CA2438272A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
10/09/2002EP1246847A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
10/09/2002EP1246843A1 Novel fgf homolog zfgf12
10/09/2002EP1246842A1 Nk cell receptor polynucleotides, polypeptides, and antibodies
10/09/2002EP1246840A2 Human and parasite orphan receptor proteins
10/09/2002EP1246835A2 Substituted sapogenins and their use
10/09/2002EP1246619A1 Urotensin-ii receptor antagonists
10/09/2002EP1049467B1 Celecoxib compositions
10/09/2002CN1373666A Medicament with protective effect against oxidative-toxic substances, particularly against cardiotoxin substances
10/09/2002CN1092056C Chinese medicine 'Kaibitong' for treating rheumatism
10/08/2002US6462089 Modafinil; restoring a normal sleep pattern; myotonic dystrophy
10/08/2002US6462065 Use of 5-HT3 receptor antagonists for treating musculoeskeletal diseases
10/08/2002CA2196769C Benzimidazole derivatives having dopaminergic activity
10/03/2002WO2002077237A2 Transporters and ion channels
10/03/2002WO2002077217A2 Human dual specificity protein phosphatase 7-like protein
10/03/2002WO2002076995A2 2-amino-propanol derivatives
10/03/2002WO2002076990A1 Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor
10/03/2002WO2002076989A1 Protein phosphate inhibitors
10/03/2002WO2002076983A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors
10/03/2002WO2002076979A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
10/03/2002WO2002076964A1 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same
10/03/2002WO2002076939A2 Cysteine protease inhibitors
10/03/2002WO2002076404A2 Fatty alcohol drug conjugates
10/03/2002WO2001089543A3 Use of proanthocyanidins as an active ingredient of a stimulator and l-arginine or its salts as a source of nitric oxide to relieve symptoms of erectile dysfuntion
10/03/2002WO2001071004A3 Proteases
10/03/2002WO2001021812A9 Phosphatases which activate map kinase pathways
10/03/2002US20020143149 Seven trans-membrane receptor-Fitz2
10/03/2002US20020143032 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
10/03/2002US20020143029 Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity
10/03/2002US20020143026 Induce mitotic arrest thereby making them useful as anti-cancer agents; also for therapy of diseases which can be treated by inducing mitotic arrest
10/03/2002US20020143010 Compounds for treating fibromyalgia and chronic fatigue syndrome
10/03/2002US20020142330 Novel glutamate receptor modulatory proteins and nucleic acid molecules and uses therefor
10/03/2002US20020142045 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/03/2002US20020142010 Administering neurotoxin
10/03/2002CA2442178A1 2-amino-propanol derivatives
10/03/2002CA2441790A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
10/03/2002CA2441455A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors
10/03/2002CA2441377A1 Protein phosphate inhibitors
1 ... 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 ... 233